Posted by Michael Wonder on 23 Oct 2018
Compass Pathways receives FDA breakthrough therapy designation for psilocybin therapy for treatment-resistant depression
23 October 2018 - Compass Pathways has received breakthrough therapy designation from the US FDA for its psilocybin therapy for treatment-resistant depression.
Breakthrough therapy designation is a significant milestone for psilocybin therapy and psilocybin research, and a testament to the work done over many years by research teams in the US, the UK and Switzerland. The Heffter Research Institute was the first to fund research in this field, and supported early studies at Johns Hopkins University, New York University, and Harbor-UCLA. In the UK, the Medical Research Council backed the proof-of-concept study of psilocybin for treatment-resistant depression at Imperial College London in 2015.
Compass Pathways is now running the first large-scale psilocybin therapy clinical trial for treatment-resistant depression, which will take place in Europe and North America over the next year or so.
